2026-07-23T17:42:57Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/138172024-09-27T21:18:51Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Bai, Xilian author Borrow, Ray author Bukovski, Suzana author Caugant, Dominique A author Culic, Davor author Delic, Snezana author Dinleyici, Ener Cagri author Eloshvili, Medeia author Erdősi, Tímea author Galajeva, Jelena author Křížová, Pavla author Lucidarme, Jay author Mironov, Konstantin author Nurmatov, Zuridin author Pana, Marina author Rahimov, Erkin author Savrasova, Larisa author Skoczyńska, Anna author Smith, Vinny author Taha, Muhamed-Kheir author Titov, Leonid author Vazquez-Moreno, Julio Alberto author Yeraliyeva, Lyazzat author 2019-12 The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. J Infect. 2019 Dec;79(6):528-541. 10.1016/j.jinf.2019.10.018 1532-2742 The Journal of Infection 31682877 http://hdl.handle.net/20.500.12105/13817 Antibiotic resistance Bacterial meningitis Conjugate vaccine Eastern Europe High-risk groups Immunization program Meningococcal disease Neisseria meningitidis Polysaccharide vaccine Refugees Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe